Cargando…

Role of Ureteroscopy (URS) and Stone Treatment in Patients with Recurrent UTIs: Outcomes over a 10-Year Period

Background. The study aimed to assess whether the eradication of kidney stones might result in a substantial reduction in the onset of recurrent UTIs. Methods. We selected all the patients who underwent ureteroscopy (URS) for stone disease between 2012 and 2021, with either a history of recurrent UT...

Descripción completa

Detalles Bibliográficos
Autores principales: Ripa, Francesco, Massella, Virginia, Ong, Andrea, Mani Sinha, Mriganka, Pietropaolo, Amelia, Somani, Bhaskar K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219553/
https://www.ncbi.nlm.nih.gov/pubmed/37240697
http://dx.doi.org/10.3390/jcm12103591
_version_ 1785049037159792640
author Ripa, Francesco
Massella, Virginia
Ong, Andrea
Mani Sinha, Mriganka
Pietropaolo, Amelia
Somani, Bhaskar K.
author_facet Ripa, Francesco
Massella, Virginia
Ong, Andrea
Mani Sinha, Mriganka
Pietropaolo, Amelia
Somani, Bhaskar K.
author_sort Ripa, Francesco
collection PubMed
description Background. The study aimed to assess whether the eradication of kidney stones might result in a substantial reduction in the onset of recurrent UTIs. Methods. We selected all the patients who underwent ureteroscopy (URS) for stone disease between 2012 and 2021, with either a history of recurrent UTIs (rUTIs), urosepsis or pre-operative positive urine culture (UC). Data included patient demographics, microbiological data, stone parameters, stone-free and infection-free rates (SFR and IFR, respectively) at follow-up, defined as fragments <2 mm at imaging and the absence of symptoms and urine-culture-proven UTI. Results. Overall, 178 patients were selected. The median age was 62 years. The median cumulative stone size was 10 mm (7–17.25), and the commonest locations were the lower pole (18.9%) and proximal ureter (14.9%). The overall stone-free rate at follow-up was 89.3%. The IFR at 3 months was 88.3%. As follow-up duration increased, the IFR reduced to 85.4%, 74.2%, 68% and 65% at 6, 12, 18 and 24 months, respectively. Patients who had infection recurrence were more likely to present stone persistence or recurrence compared to those who were infection-free at follow-up (20% vs. 4.4%, p = 0.005). Conclusions. SFR after URS is a significant predicting variable for the likelihood of infection-free status at follow-up in patients with an rUTI or positive UC at the time of URS.
format Online
Article
Text
id pubmed-10219553
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102195532023-05-27 Role of Ureteroscopy (URS) and Stone Treatment in Patients with Recurrent UTIs: Outcomes over a 10-Year Period Ripa, Francesco Massella, Virginia Ong, Andrea Mani Sinha, Mriganka Pietropaolo, Amelia Somani, Bhaskar K. J Clin Med Article Background. The study aimed to assess whether the eradication of kidney stones might result in a substantial reduction in the onset of recurrent UTIs. Methods. We selected all the patients who underwent ureteroscopy (URS) for stone disease between 2012 and 2021, with either a history of recurrent UTIs (rUTIs), urosepsis or pre-operative positive urine culture (UC). Data included patient demographics, microbiological data, stone parameters, stone-free and infection-free rates (SFR and IFR, respectively) at follow-up, defined as fragments <2 mm at imaging and the absence of symptoms and urine-culture-proven UTI. Results. Overall, 178 patients were selected. The median age was 62 years. The median cumulative stone size was 10 mm (7–17.25), and the commonest locations were the lower pole (18.9%) and proximal ureter (14.9%). The overall stone-free rate at follow-up was 89.3%. The IFR at 3 months was 88.3%. As follow-up duration increased, the IFR reduced to 85.4%, 74.2%, 68% and 65% at 6, 12, 18 and 24 months, respectively. Patients who had infection recurrence were more likely to present stone persistence or recurrence compared to those who were infection-free at follow-up (20% vs. 4.4%, p = 0.005). Conclusions. SFR after URS is a significant predicting variable for the likelihood of infection-free status at follow-up in patients with an rUTI or positive UC at the time of URS. MDPI 2023-05-22 /pmc/articles/PMC10219553/ /pubmed/37240697 http://dx.doi.org/10.3390/jcm12103591 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ripa, Francesco
Massella, Virginia
Ong, Andrea
Mani Sinha, Mriganka
Pietropaolo, Amelia
Somani, Bhaskar K.
Role of Ureteroscopy (URS) and Stone Treatment in Patients with Recurrent UTIs: Outcomes over a 10-Year Period
title Role of Ureteroscopy (URS) and Stone Treatment in Patients with Recurrent UTIs: Outcomes over a 10-Year Period
title_full Role of Ureteroscopy (URS) and Stone Treatment in Patients with Recurrent UTIs: Outcomes over a 10-Year Period
title_fullStr Role of Ureteroscopy (URS) and Stone Treatment in Patients with Recurrent UTIs: Outcomes over a 10-Year Period
title_full_unstemmed Role of Ureteroscopy (URS) and Stone Treatment in Patients with Recurrent UTIs: Outcomes over a 10-Year Period
title_short Role of Ureteroscopy (URS) and Stone Treatment in Patients with Recurrent UTIs: Outcomes over a 10-Year Period
title_sort role of ureteroscopy (urs) and stone treatment in patients with recurrent utis: outcomes over a 10-year period
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219553/
https://www.ncbi.nlm.nih.gov/pubmed/37240697
http://dx.doi.org/10.3390/jcm12103591
work_keys_str_mv AT ripafrancesco roleofureteroscopyursandstonetreatmentinpatientswithrecurrentutisoutcomesovera10yearperiod
AT massellavirginia roleofureteroscopyursandstonetreatmentinpatientswithrecurrentutisoutcomesovera10yearperiod
AT ongandrea roleofureteroscopyursandstonetreatmentinpatientswithrecurrentutisoutcomesovera10yearperiod
AT manisinhamriganka roleofureteroscopyursandstonetreatmentinpatientswithrecurrentutisoutcomesovera10yearperiod
AT pietropaoloamelia roleofureteroscopyursandstonetreatmentinpatientswithrecurrentutisoutcomesovera10yearperiod
AT somanibhaskark roleofureteroscopyursandstonetreatmentinpatientswithrecurrentutisoutcomesovera10yearperiod